FERMENTA BIOTECH LTD.

Fermenta Biotech Limited was formerly incorporated as 'Duphar-Interfran Limited' in May, 1951. The Company name was changed to 'DIL Limited' in September, 2003 and later on, was changed to 'Fermenta Biotech Limited' on October 17, 2019. The Company is presently engaged in pharmaceuticals, manufacturing and marketing Active Pharmaceutical Ingredients, biotechnology, environmental solutions and renting of properties. Initially, Company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities. It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the Company to the extent of 25% each. In 1964, Company entered into a collaboration with Solvay Duphar to manufacture vitamin D3. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%. Company came out with a rights issue in May '95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, Lacto-Calamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs. As per the Scheme of Arrangement, the Pharma Division of the Company was transferred to Duphar Pharma India. The Company has made investments in unutilised premises at Thane to create a commercial complex with modern facilities so that substantial portion of it can be let out to earn income. The successful entry of Annual Contract with Solvay Pharmaceuticals B V of Netherlands will definitely establish as a reliable contract research organization for Duphar Interfran Ltd. As mutual consent with Solvay Pharmaceuticals,Netherlands,the company has been permitted to continue with the name DUPHAR for a limited time. It has also been decided to change the name to DIL Limited from Duphar-Interfran Ltd. With the prior approval from Board the company has acquired 990,000 equity shares of Rs.10 each in Fermenta Biotech Ltd there by increase its holding to 83.71% comprising 16,57,500 equity shares. Subsequent to this FBL will henceforth be a subsidiary of Duphar Interfran Ltd. In 2003, the Company expanded manufacturing capacity with Vitamin D and other products such as Phenyramidol at Kullu. During the year 2009-10, the Company carried out the Drug Discovery and Development Services through its subsidiaries, Evotec (India) Private Limited and its subsidiary Evotec-RSIL Limited up to August 31, 2009. Through the divestment of 70% equity shares by the Company in Evotec (India) Private Limited, Evotec (India) Private Limited and its subsidiary Evotec-RSIL Limited ceases to be subsidiaries of the Company with effect from September 01, 2009. New projects were undertaken with Bayer CropSciences, Novartis, Boehringer Ingelheim and Chugai. The Company commissioned a new manufacturing facility at Dahej SEZ, Gujarat during 2010-11. The Company executed a definitive agreements with a private equity investor in Mauritius, Evolvence India Life Sciences Fund LLC (EILSF) on December 10, 2010 for sale of 1,915,036 equity shares held by Company in FBL to EILSF and issue of an equal number of fresh equity shares by FBL to EILSF, for a total consideration of Rs. 40 crores, which was completed in Jan'11. It launched new and improved Penicillin G Acylase catalyst - Fermase PA 850 in 2012. Agastya Films LLP and Zela Wellness Private Limited ceased to be joint venture entity and associate company w.e.f. January 01, 2019 and Novemeber 29, 2018 respectively. The Company in FY 2019-20, launched a new product, fish oil derived cholesterol, for the aquaculture market, it launched a new version of Vitamin D 500 feed grade powder in 2020. During the year 2019-20, the Scheme of Amalgamation between the Parent i.e. DIL Limited (DIL) and its subsidiary, Fermenta Biotech Limited (FBL) and their respective shareholders became effective from September 26, 2019, with the appointed date as April 01, 2018. On September 5, 2019, the Company's subsidiary viz. Fermenta Biotech GmbH was incorporated in Germany. The Company incorporated a wholly-owned subsidiary in the United States of America viz. Fermenta Biotech USA LLC on May 27, 2020. In December 2020, Fermenta Biotech USA LLC, a wholly owned subsidiary of the Company, acquired 52% membership interest in AGD Nutrition, LLC (now known as Fermenta USA, LLC). In FY 2021-22, the Company launched Vitamin AD2 for oil fortification and developed patented technology for enzymatic synthesis of Molnupiravir. The Company commissioned a a manufacturing facility for Fortified Rice Kernel (FRK) in Pennepalli, Andhra Pradesh in 2022. The Scheme of Amalgamation amongst DVK Investments Private Limited and Aegean Properties Limited and the Company and their respective Shareholders was made effective on May 24, 2023. Post Effective Date, the Company issued and allotted 150,75,318 equity shares of face value of Rs. 5/- each, fully paid-up, to the members of DVK Investments Private Limited on June 02, 2023. As per the terms of NCLT Order dated May 8, 2023 regarding Composite Scheme of Amalgamation and Arrangement, the Company's Holding company, DVK Investments Private Limited and the Company's subsidiary, Aegean Properties Limited ceased to exist w.e.f. May 24, 2023. The Company commissioned its Customized Premixing Plant in Kullu, Himachal Pradesh in 2024. The Company transferred plant-source Vitamin D3 technology from R&D to manufacturing EU GMP and US FDA certifications for Dahej facility in FY 2024-25.